FY2024 EPS Estimates for Personalis Reduced by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Analysts at HC Wainwright decreased their FY2024 EPS estimates for Personalis in a research note issued to investors on Monday, January 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.36) per share for the year, down from their previous forecast of ($1.29). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.05) EPS.

Several other research analysts also recently weighed in on PSNL. Lake Street Capital upped their target price on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $7.25 price objective on shares of Personalis in a research report on Wednesday, January 8th.

Personalis Stock Performance

Personalis stock opened at $5.01 on Wednesday. Personalis has a one year low of $1.12 and a one year high of $7.20. The stock’s 50 day moving average price is $4.93 and its 200 day moving average price is $4.75. The firm has a market capitalization of $353.95 million, a PE ratio of -2.98 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. During the same period last year, the business earned ($0.51) earnings per share.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC bought a new stake in shares of Personalis in the 3rd quarter worth about $40,000. SG Americas Securities LLC acquired a new position in Personalis in the fourth quarter worth about $63,000. China Universal Asset Management Co. Ltd. bought a new stake in Personalis in the fourth quarter valued at about $87,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after buying an additional 4,504 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after buying an additional 17,082 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.